Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

UNC to test new assist device for failed livers

12.03.2003




Prospects for surviving acute liver failure are very slim, and statistics place mortality as high as 90 percent. A liver transplant may be the only alternative before fatal complications set in, yet not enough donor organs are available to meet the demand.

But a new bio-artificial technology about to undergo clinical tests at the University of North Carolina at Chapel Hill and several other centers nationally may help extend the lives of those awaiting a donor liver and may even allow the damaged liver to heal itself completely.

Known by its acronym ELAD, the extracorporeal liver assist device is the first such technology to contain functioning human hepatocytes, liver cells that help sustain and support the work of the patient’s damaged and failed organ. Other liver assist systems use hepatocytes from pigs.



The new device is a closed system to which patients are tethered via a catheter inserted into a vein in the neck. After the blood is initially filtered, the remaining plasma goes through cartridges in the ELAD where the human hepatocytes help fulfill much of the liver’s 100 or so crucial functions, such as energy storage and regulation, bile production, blood detoxification, production of clotting factors and many essential proteins. The filtered blood and ELAD-treated plasma are returned to the patient.

Dr. Roshan Shrestha, associate professor of medicine and medical director of the liver transplantation program at UNC, said ELAD could provide two major benefits.

"This device could serve as a bridge to successful transplantation, helping to sustain patients awaiting a donor organ."

It also may enable complete recovery, he added.

"A remarkable feature of the liver is its capacity to regenerate. If we can sustain acute liver failure patients early on, right from the beginning, they may not need transplantation and may recover without any significant liver problems, including chronic liver disease."

Shrestha, principal investigator for the UNC study site, said a first-phase clinical trial conducted in the United States and Great Britain during 1999 and 2000 showed promising results. In that study, sponsored by ELAD maker Vitagen Inc., 11 of 12 (91.6 percent) of patients who had been randomized to receive treatment with the new device achieved either a successful bridge to transplantation or full recovery. In a control group of patients receiving standard care, three of seven (42 percent) achieved those benefits.

In an analysis of overall results in 25 patients, including those not listed for liver transplantation, 13 of 16 (81 percent) improved on the device, compared to only five of nine (51 percent) in the control group.

Shrestha said the U.S. Food and Drug Administration was sufficiently pleased with the results to give its nod to a second-phase trial, also sponsored by Vitagen. Safety and effectiveness, including survival at 30 days, is the main endpoint, Shrestha said.

"The primary objective is to evaluate the safety, efficacy and tolerability of the ELAD system in patients with acute hepatic [liver] failure. Our secondary objective is to evaluate the study protocol with respect to patient inclusion and exclusion criteria and to study the system’s performance with regard to endpoints." Total enrollment for this trial is between 30 and 40 patients. A larger third-phase trial may follow, with an enrollment of at least 200 people with acute liver failure.

"Currently, we don’t have very good therapies for patients with acute liver failure. That’s why we’re hoping that the new technology will make a big difference," Shrestha said. "The bottom line is to save lives."


Note: Contact Shrestha at (919) 843-9459 or (919) 966-2516 (choose option "O"), or r_shrestha@med.unc.edu.

School of Medicine contact: Les Lang, (919) 843-9687 or llang@med.unc.edu


Leslie H. Lang | EurekAlert!
Further information:
http://www.med.unc.edu/

More articles from Health and Medicine:

nachricht Chances to treat childhood dementia
24.07.2017 | Julius-Maximilians-Universität Würzburg

nachricht World first: Massive thrombosis removed during early pregnancy
20.07.2017 | Universitätsspital Bern

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: 3-D scanning with water

3-D shape acquisition using water displacement as the shape sensor for the reconstruction of complex objects

A global team of computer scientists and engineers have developed an innovative technique that more completely reconstructs challenging 3D objects. An ancient...

Im Focus: Manipulating Electron Spins Without Loss of Information

Physicists have developed a new technique that uses electrical voltages to control the electron spin on a chip. The newly-developed method provides protection from spin decay, meaning that the contained information can be maintained and transmitted over comparatively large distances, as has been demonstrated by a team from the University of Basel’s Department of Physics and the Swiss Nanoscience Institute. The results have been published in Physical Review X.

For several years, researchers have been trying to use the spin of an electron to store and transmit information. The spin of each electron is always coupled...

Im Focus: The proton precisely weighted

What is the mass of a proton? Scientists from Germany and Japan successfully did an important step towards the most exact knowledge of this fundamental constant. By means of precision measurements on a single proton, they could improve the precision by a factor of three and also correct the existing value.

To determine the mass of a single proton still more accurate – a group of physicists led by Klaus Blaum and Sven Sturm of the Max Planck Institute for Nuclear...

Im Focus: On the way to a biological alternative

A bacterial enzyme enables reactions that open up alternatives to key industrial chemical processes

The research team of Prof. Dr. Oliver Einsle at the University of Freiburg's Institute of Biochemistry has long been exploring the functioning of nitrogenase....

Im Focus: The 1 trillion tonne iceberg

Larsen C Ice Shelf rift finally breaks through

A one trillion tonne iceberg - one of the biggest ever recorded -- has calved away from the Larsen C Ice Shelf in Antarctica, after a rift in the ice,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Closing the Sustainability Circle: Protection of Food with Biobased Materials

21.07.2017 | Event News

»We are bringing Additive Manufacturing to SMEs«

19.07.2017 | Event News

The technology with a feel for feelings

12.07.2017 | Event News

 
Latest News

Ultrathin device harvests electricity from human motion

24.07.2017 | Power and Electrical Engineering

Scientists announce the quest for high-index materials

24.07.2017 | Materials Sciences

ADIR Project: Lasers Recover Valuable Materials

24.07.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>